Partnering, Pharma

Amgen signs a pharma licensing agreement with Carmot

Posted on 15 January 2014

Tags: , ,

Carmot Therapeutics has entered into a collaboration and pharma license agreement with Amgen.

Carmot will apply its proprietary Chemotype Evolution to discover novel drug leads for two targets selected by Amgen.

Carmot and Amgen will work together to identify and optimize drug candidates, while Amgen will be solely responsible for their clinical development.

Carmot will receive an upfront payment, research funding, and pre-clinical and clinical milestone payments.

In addition, a royalty will be paid on commercial sales of products emerging from the collaboration.

View the full article at MarketWatch

For further deal information visit Current Agreements (subscription required)

 

Related

Report: Partnering Deals and Alliances with Amgen

Report: Partnering Deals and Alliances with Genzyme

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply